亞太藥業(002370.SZ)收到藥品註冊受理通知書 涉頭孢克肟膠囊
格隆匯 10 月 14日丨亞太藥業(002370.SZ)公佈,公司於近日收到國家藥品監督管理局下發的藥品註冊受理通知書,產品名稱:頭孢克肟膠囊。
頭孢克肟膠囊為口服第三代頭孢菌素,抗菌譜廣,對部分革蘭氏陽性菌及陰性菌均具有抗菌活性,特別是對革蘭氏陽性菌中的鏈球菌(腸球菌除外)、肺炎球菌,革蘭氏陰性菌中的淋球菌、布蘭漢氏球菌、大腸菌、克雷伯氏屬、沙雷氏屬、變形桿菌屬、流感桿菌等有較強的抗菌作用,其作用機制為殺菌性的。本品對各種細菌產生的β-內酰胺酶具有較強的穩定性,對產生β-內酰胺酶細菌顯示優越的抗菌力。本品作用機制為阻止細菌細胞壁的合成,其作用點因細菌的種類而異,與青黴素結合蛋白(PBP)中l(la,lb,lc)以及3有較高親和性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.